The effect of atomoxetine on random and directed exploration in humans
AuthorWarren, Christopher M.
Wilson, Robert C.
van der Wee, Nic J.
Giltay, Eric J.
van Noorden, Martijn S.
Cohen, Jonathan D.
AffiliationUniv Arizona, Dept Psychol
Univ Arizona, Cognit Sci Program
MetadataShow full item record
PublisherPUBLIC LIBRARY SCIENCE
CitationThe effect of atomoxetine on random and directed exploration in humans 2017, 12 (4):e0176034 PLOS ONE
Rights© 2017 Warren et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractThe adaptive regulation of the trade-off between pursuing a known reward ( exploitation) and sampling lesser-known options in search of something better ( exploration) is critical for optimal performance. Theory and recent empirical work suggest that humans use at least two strategies for solving this dilemma: a directed strategy in which choices are explicitly biased toward information seeking, and a random strategy in which decision noise leads to exploration by chance. Here we examined the hypothesis that random exploration is governed by the neuromodulatory locus coeruleus-norepinephrine system. We administered atomoxetine, a norepinephrine transporter blocker that increases extracellular levels of norepinephrine throughout the cortex, to 22 healthy human participants in a double-blind crossover design. We examined the effect of treatment on performance in a gambling task designed to produce distinct measures of directed exploration and random exploration. In line with our hypothesis we found an effect of atomoxetine on random, but not directed exploration. However, contrary to expectation, atomoxetine reduced rather than increased random exploration. We offer three potential explanations of our findings, involving the non-linear relationship between tonic NE and cognitive performance, the interaction of atomoxetine with other neuromodulators, and the possibility that atomoxetine affected phasic norepinephrine activity more so than tonic norepinephrine activity.
NoteOpen access journal.
VersionFinal published version
SponsorsEuropean Research Council [StG_2011 283314]
- Humans use directed and random exploration to solve the explore-exploit dilemma.
- Authors: Wilson RC, Geana A, White JM, Ludvig EA, Cohen JD
- Issue date: 2014 Dec
- Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase.
- Authors: Warren CM, van den Brink RL, Nieuwenhuis S, Bosch JA
- Issue date: 2017 Apr
- Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing.
- Authors: Bieck PR, Leibowitz M, Lachno DR, Ledent E, Padich R, Jhee S
- Issue date: 2016 Dec
- Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.
- Authors: Bradshaw SE, Agster KL, Waterhouse BD, McGaughy JA
- Issue date: 2016 Jun 15
- Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.
- Authors: Okamoto LE, Shibao C, Gamboa A, Choi L, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I
- Issue date: 2012 Mar